» Articles » PMID: 19133980

Glucocorticoid Resistance in a Multiple Myeloma Cell Line is Regulated by a Transcription Elongation Block in the Glucocorticoid Receptor Gene (NR3C1)

Overview
Journal Br J Haematol
Specialty Hematology
Date 2009 Jan 13
PMID 19133980
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Glucocorticoid (GC) effects are mediated by the glucocorticoid receptor (GR). Several studies have demonstrated that a lower number of receptors per cell were associated with poor GC response. The regulation of GR expression is complex; the levels of GR can be autologously regulated by its ligand and also by transcriptional, post-transcriptional and post-translational mechanisms. Using three human myeloma cell lines that parallel the development of GC resistance, this work describes the mechanism involved in the downregulation of GR expression. The decreased expression was neither due to mutations in the gene encoding GR, NR3C1, nor due to methylation of the promoters. A gradual decrease in NR3C1 transcripts was seen during the development of resistance, the level of expression of exon 1 to 2 RNA fragments remained the same in sensitive and resistant cell lines but a chromatin immunoprecipitation assay demonstrated that RNA polymerase II, detectable throughout exon 2 to 3 in the sensitive cells, was undetectable on exon 3 in the resistant variant, suggesting lower or no transcription at this site. These studies demonstrated that downregulation of NR3C1 mRNA in a resistant cell line involves a block to transcriptional elongation within intron B of NR3C1. This block may represent an important element in the regulation of GR expression.

Citing Articles

Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.

Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T Heliyon. 2024; 10(12):e33091.

PMID: 39021902 PMC: 11252793. DOI: 10.1016/j.heliyon.2024.e33091.


Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Clarisse D, Prekovic S, Vlummens P, Staessens E, Van Wesemael K, Thommis J Cell Mol Life Sci. 2023; 80(9):249.

PMID: 37578563 PMC: 10425521. DOI: 10.1007/s00018-023-04900-x.


Construction of novel hypoxia-related gene model for prognosis and tumor microenvironment in endometrial carcinoma.

Chen J, Wang G, Zhang D, Luo X, Zhang D, Zhang Y Front Endocrinol (Lausanne). 2023; 13:1075431.

PMID: 36589842 PMC: 9797861. DOI: 10.3389/fendo.2022.1075431.


Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies.

Scheijen B Cancer Drug Resist. 2022; 2(3):647-664.

PMID: 35582582 PMC: 8992511. DOI: 10.20517/cdr.2019.29.


Effect of the uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group C member 1 (NR3C1) genes on treatment efficacy and survival in patients with multiple myeloma: a single-center study.

Demir I, Pehlivan S, Okan V, Haydaroglu Sahin H, Durusoy S, Serin I BMC Res Notes. 2021; 14(1):346.

PMID: 34481515 PMC: 8418283. DOI: 10.1186/s13104-021-05758-7.


References
1.
Costlow M, Pui C, Dahl G . Glucocorticoid receptors in childhood acute lymphocytic leukemia. Cancer Res. 1982; 42(11):4801-6. View

2.
Mechti N, Piechaczyk M, Blanchard J, Jeanteur P, Lebleu B . Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene. Mol Cell Biol. 1991; 11(5):2832-41. PMC: 360067. DOI: 10.1128/mcb.11.5.2832-2841.1991. View

3.
Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies F . SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000; 275(36):27845-50. DOI: 10.1074/jbc.M003428200. View

4.
Chen C, Shyu A . AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995; 20(11):465-70. DOI: 10.1016/s0968-0004(00)89102-1. View

5.
Adcock I, Nasuhara Y, Stevens D, Barnes P . Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999; 127(4):1003-11. PMC: 1566089. DOI: 10.1038/sj.bjp.0702613. View